Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Siliq

- PMLiVE

Novartis shares positive phase 3 results for atrasentan in rare kidney disease

The company gained access to the candidate after it acquired Chinook Therapeutics

- PMLiVE

World Psoriasis Day: Almirall highlights impact of disease on patient well-being

Almost 77% of patients believe that psoriasis negatively affects their daily life and well-being

Psoriasis-Awareness-Day

Listening and hearing – how patients’ online behaviour can help us to improve wellbeing in psoriasis.

The following article was developed using information gathered through primary and secondary desk research, including a recent Social Listening project conducted by our team at Mednet.

Mednet

- PMLiVE

Eli Lilly’s Omvoh granted FDA approval for ulcerative colitis

Inflammatory bowel disease is estimated to affect nearly one in every 100 people in the US

- PMLiVE

Novartis’ Cosentyx recommended by NICE for hidradenitis suppurativa

At least 200,000 people in the UK are affected by the inflammatory skin disease

- PMLiVE

Eli Lilly and Almirall’s lebrikizumab shows sustained improvements in atopic dermatitis

The IL-13 inhibitor improved the symptoms of atopic dermatitis for up to two years

- PMLiVE

Sandoz separates from Novartis as an independent spin-off company

The split allows Sandoz to strengthen its position in generics and biosimilars

- PMLiVE

Eli Lilly to acquire cancer specialist Point Biopharma in deal worth $1.4bn

The transaction would give Lilly access to experimental radioligand therapies

- PMLiVE

Eli Lilly files US lawsuits over ‘unlawful’ sales of Mounjaro counterfeits

Lilly is the only FDA-approved company to legally sell products containing tirzepatide

- PMLiVE

Eli Lilly’s Mounjaro receives NICE recommendation to treat type 2 diabetes

Around 180,000 patients with type 2 diabetes could benefit from the new treatment option

- PMLiVE

Boehringer and Lilly’s Jardiance granted MHRA approval to treat chronic kidney disease

Approximately 7.2 million people in the UK are affected by the long-term kidney condition

- PMLiVE

Novartis sues US government over Medicare drug price negotiation programme

The action comes after the first drugs subject to pricing negotiations were announced

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links